Guest
Guest
Sep 11, 2026
1:48 AM
|
Pharmaceutical manufacturers are increasingly looking for formulation technologies that can improve drug performance while supporting more convenient routes of administration. Spray drying converts liquids or suspensions into powders and can help modify the physical properties of pharmaceutical formulations.
The pharmaceutical spray drying market was valued at approximately USD 2.2 billion in 2024 and is projected to reach USD 5.0 billion by 2035, representing a CAGR of 7.6%.
The technology can improve solubility and bioavailability and can support the development of oral and inhaled formulations. It may also allow manufacturers to develop more concentrated formulations and potentially reduce tablet size.
Spray drying has applications across APIs, inhalables, biologics and other pharmaceutical products. The technology can be particularly useful for compounds with poor aqueous solubility or products requiring specialized particle characteristics.
Aseptic spray drying is another area of interest because it can support the processing of biological and sensitive products under controlled conditions. The approval of Raplixa, a spray-dried biologic, demonstrated one potential application of the technology.
Contract manufacturing organizations are also investing in spray drying capabilities. Outsourcing allows pharmaceutical companies to access specialized equipment and process expertise without establishing dedicated infrastructure.
Equipment providers such as Buchi Labortechnik, GEA Niro, SPX FLOW and other specialized manufacturers compete alongside service providers.
As drug developers continue to pursue more complex formulations and alternative delivery routes, spray drying is likely to remain an important enabling technology.
For more information on the Pharmaceutical Spray Drying Market, visit:
https://www.rootsanalysis.com/reports/pharmaceutical-spray-drying-market/195.html
|
